Navigation Links
Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
Date:5/19/2011

SAN FRANCISCO and SEATTLE, May 19, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.  The preliminary data from the study HEP007 indicated that the risk of death for patients who received JX-594 at the high therapeutic dose was markedly reduced by more than 50 percent (hazard ratio < 0.5) when compared to patients randomized to a control low dose (one-tenth of the high dose). Clinical investigators enrolled approximately 30 patients at sites in the United States, Canada and South Korea.

The data were presented by David Kirn, M.D., president and chief executive officer of Jennerex, today in an oral presentation in the Presidential Symposium of the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Seattle, Washington.  These data were also chosen for inclusion in ASGCT's Media Event to be held during the annual meeting.  Jennerex and its partners expect to present further follow-up on the complete trial data set at a medical conference later this year.

A randomized, placebo-controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (HCC) having failed sorafenib-(Nexavar®) treatment is planned for initiation in the second half of this year; this trial (TRAVERSE), conducted globally with Jennerex's partners, will evaluate survival in advanced HCC patients who have either progressed or exhibited intolerance after treatment with sorafenib, the current standard of care.

"We are extremely encouraged by the promising overall survival results presented today. These results are consistent with a clinically meaningful survival benefit in patients wit
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... and REHOVOT, Israel , August ... medical 3D printing specialist, Replica 3DM, supports NHS hospitals with ... Printers   - Performing surgery on ... anesthetic times; improves patient recovery and provides an effective aid ... Stratasys Ltd. (Nasdaq: SSYS ), a global ...
(Date:8/26/2014)... , Aug. 26, 2014   Lycera Corp ... breakthrough oral medicines to treat autoimmune disease and ... today announced the appointment of Harinder Singh ... advisory board.  Dr. Singh will lead the board,s ... Lycera,s multiple ongoing research programs and pipeline of ...
(Date:8/26/2014)... Vycom announced today that Modutek Corporation ... equipment, has selected its Flametec materials for a ... Beams (FRIB). This involved the creation of a ... Flametec PVC-C and Kytec PVDF material to clean superconducting ... linear accelerator (known as LINAC). , ...
(Date:8/26/2014)...   Loveland Products, a subsidiary of Agrium and ... products and proprietary products provider for Agrium Retail ... a controlling interest in Agricen, a ... products for efficient and sustainable plant nutrition. Agricen ... nutrition brands, Accomplish ® LM and Titan ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 2Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 3Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 4
... from a chimp? Researchers from the European Molecular ... one important step closer to answering such evolutionary ... Science they uncover systematic errors in existing ... to learn about their evolutionary relationships. They present ...
... JumpStart Inc., the Northeast Ohio,venture development ... businesses and ideas, has announced an investment ... The JumpStart,investment is part of a recently ... RMS Management of Cleveland, OH., (Logo: ...
... EMERYVILLE, Calif., June 19 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... present,at the Jefferies 2nd Annual Healthcare Conference on ... parties may access a live webcast of,the presentation ... It is recommended that listeners log on ...
Cached Biology Technology:Scientists fix bugs in our understanding of evolution 2JumpStart Invests in Tursiop Technologies 2JumpStart Invests in Tursiop Technologies 3
(Date:8/27/2014)... what is described by the Volunteer Wildfire Services of ... Cape provincial government warned residents in certain parts of ... veld fires. A high veld fire danger rating ... coast in the Great Kei and Mnquma area. ... thunderstorms. The thunderstorms bring lightning strikes and subsequent ...
(Date:8/27/2014)... consumers are willing to pay a premium for fruits, ... getting what the label claims is another matter. Now ... new way to make sure farms are labelling their ... Journal of Agricultural and Food Chemistry , could help ... Health and Food Safety Authority and the Wuerzburg University ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
Breaking Biology News(10 mins):
... hope a vaccine is on the horizon for tularemia, a ... an organism of concern as a potential biological warfare agent. ... according to the August issue of the Journal of ... and rapid progress has been made in understanding how it ...
... in a new 5,000-square-foot exhibition, "Dig it! The Secrets ... D.C. The exhibition will travel to museums across the ... experts, along with the President of the Soil Science ... the new "Dig It! The Secrets of Soil" exhibition, ...
... research published in the July issue of the Journal ... DNA is a reliable marker of recurrent esophageal cancer. The ... evidence of cancer recurrence in the majority of patients. ... cancer death worldwide, is usually diagnosed at a late stage. ...
Cached Biology News:Francisella tularensis: Stopping a biological weapon 2Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds 2
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
Request Info...
Applications: (+) Immunocytochemistry and immunohistochemistry...
RABBIT ANTI WARFARIN...
Biology Products: